Monoclonal antibody therapy for pancreas cancer
AssigneePrecision Biologics, Inc.
InventorsMyron Arlen, Kwong Tsang
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.
Claims34
(canceled)
(canceled)
An isolated nucleic acid molecule comprising a nucleotide sequence that (i) binds to the nucleotide sequence of FIG. 2 or FIG. 4 under the following stringent hybridization conditions:
- 0.5 M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°, and washing in 0. 1×SSC/0. 1% SDS at 68° and (ii) encodes for a light or heavy chain variable region capable of binding with the same immunospecificity as the chimeric 31.1 monoclonal antibody.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of killing cells that express carrying a pancreatic carcinoma associated antigen, comprising delivering to said cells an effective amount of a 31.1 monoclonal antibody.
The method of claim 36, wherein said radiological study comprises a chest X-ray, computerized tomography, magnetic resonance imaging, or ultrasound.
Dependencies are inferred from the claim text.